Literature DB >> 14611676

Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma.

Morio Sawada1, Hitoshi Tsuda, Mikihiko Kimura, Sanshiro Okamoto, Tsunekazu Kita, Takahiro Kasamatsu, Takuro Yamada, Yoshihiro Kikuchi, Hideo Honjo, Osamu Matsubara.   

Abstract

Uterine carcinosarcoma histologically comprises the components of epithelial and mesenchymal malignancies, and is known to be clinically highly aggressive. To reveal the significance of the expression of tyrosine-kinase-receptor-type oncoproteins in this tumor type, the incidence and distribution of the KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins were immunohistochemically examined in 16 surgically resected cases. For 6 cases, the EGFR and HER-2 amplifications were also examined by fluorescence in situ hybridization (FISH). In the epithelial component, overexpressions of KIT, EGFR, and HER-2 were detected in 4 (25%), 5 (31%), and 9 (56%) cases, respectively, whereas these overexpressions in the mesenchymal component were detected in 6 (38%), 8 (50%), and 1 (6%) cases, respectively. KIT and EGFR were co-overexpressed in the mesenchymal component of 4 cases and in the epithelial component of 2 cases. However, HER-2 overexpression was mostly detected in the epithelial component only, and tended to occur independently of KIT and/or EGFR overexpression. By FISH, one of the 4 cases with HER-2 overexpression showed low-level gene amplification. In two cases with EGFR overexpression, the gain of EGFR alleles and/or polyploidization of chromosome 7 had occurred. The expression patterns of KIT, EGFR, and HER-2 differed between the epithelial and mesenchymal components, and the regulation of their expression appeared important in the acquisition of mesenchymal metaplasia in uterine carcinosarcoma. Structural and/or numerical alterations of chromosomes might be in part involved in EGFR and/or HER-2 overexpression in this tumor type.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14611676     DOI: 10.1111/j.1349-7006.2003.tb01389.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  17 in total

1.  T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Authors:  Roberta Nicoletti; Salvatore Lopez; Stefania Bellone; Emiliano Cocco; Carlton L Schwab; Jonathan D Black; Floriana Centritto; Liancheng Zhu; Elena Bonazzoli; Natalia Buza; Pei Hui; Delia Mezzanzanica; Silvana Canevari; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2014-11-15       Impact factor: 5.150

2.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

Review 3.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  Association between the HER2 expression and histological differentiation in Wilms tumor.

Authors:  M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

5.  Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.

Authors:  Hiroshi Yoshida; Tadaaki Nishikawa; Koji Matsumoto; Masahiko Mori; Yasuyuki Hirashima; Kazuhiro Takehara; Kazuya Ariyoshi; Kosei Hasegawa; Kan Yonemori
Journal:  Virchows Arch       Date:  2021-01-09       Impact factor: 4.064

6.  Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.

Authors:  Lei Zhang; David Shimizu; Jeffrey L Killeen; Stacey A Honda; Di Lu; Alexander Stanoyevitch; Fritz Lin; Beverly Wang; Edwin S Monuki; Michele Carbone
Journal:  Hum Pathol       Date:  2016-03-11       Impact factor: 3.466

Review 7.  Review of Recommended Treatment of Uterine Carcinosarcoma.

Authors:  Joseph Menczer
Journal:  Curr Treat Options Oncol       Date:  2015-11

Review 8.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 9.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

10.  SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Authors:  Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.